Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
Eli Lilly and Company
National Capital Foundation
Age
18–100
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Have metastatic castration-resistant prostate cancer
Must have had prior abiraterone treatment
Life expectancy of greater than 3 months
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2
Age ≥18 years
Have measurable disease
Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator).
Ability to take oral medication
Patients must have adequate organ and marrow function defined by study-specified laboratory tests
Must use acceptable form of birth control while on study
Ability to understand and willingness to sign a written informed consent document
You may not be if
Known history or evidence of brain metastases
Prior chemotherapy for metastatic disease in castration-resistant prostate cancer
Had surgery within 4 weeks prior to the first dose of study drug
Had radiation, biological, or other investigational cancer therapy within 2 weeks prior to the first dose of study drug
Had second-line hormonal therapy within 2 weeks prior to the first dose of study drug
Systemic steroids within 1 weeks prior to the first dose of study drug
Had prior enzalutamide, ARN-509, or galeterone therapy
Have moderate or severe cardiovascular disease
Have a history of a seizure
Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements
Have a history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythmatosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis)
Have known history of infection with HIV, hepatitis B, or hepatitis C
